tiprankstipranks

VYNE Therapeutics Reports Q1 2025 Financial Results

VYNE Therapeutics Reports Q1 2025 Financial Results

Vyne Therapeutics Inc ( (VYNE) ) has released its Q1 earnings. Here is a breakdown of the information Vyne Therapeutics Inc presented to its investors.

Confident Investing Starts Here:

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops therapies for chronic inflammatory and immune-mediated conditions, focusing on unmet medical needs with its proprietary BET inhibitors.

In its first quarter of 2025, VYNE Therapeutics reported a net loss of $8.6 million, with revenues totaling $0.2 million. The company is advancing its Phase 2b trial for repibresib gel, targeting vitiligo, with results expected mid-year, while addressing a clinical hold on its VYN202 psoriasis trial.

Key financial highlights include a cash position of $50.3 million, expected to sustain operations into the second half of 2026. Research and development expenses increased to $6.1 million, driven by ongoing trials, while general and administrative expenses decreased slightly to $3.3 million.

Looking ahead, VYNE Therapeutics remains focused on progressing its clinical trials and resolving the clinical hold on VYN202, with a strategic emphasis on addressing significant unmet needs in dermatology and immunology.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1